BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...of generic competition in the U.S. for Somatuline...
...years. In the first nine months of 2020, Somatuline...
...U.S. operations humming if its best-selling drug, Somatuline...
BioCentury | Mar 1, 2019
Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

...he said. The company also plans to offer early access programs worldwide. Ipsen markets Somatuline lanreotide acetate...
BioCentury | Feb 25, 2019
Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

...he said. The company also plans to offer early access programs worldwide. Ipsen markets Somatuline lanreotide acetate...
BioCentury | Feb 14, 2019
Company News

Ipsen expects to hit 2020 revenue guidance early

...said the growth was driven by global market volume gains for neuroendocrine tumor therapy Somatuline lanreotide acetate...
...undisclosed program was submitted in December. Ipsen was up €8.40 to €118 on Euronext Thursday. Stephen Hansen Ipsen Somatuline...
BioCentury | Nov 3, 2017
Strategy

Broadening Novartis’ NET

...Novartis markets long-acting somatostatin analog Sandostatin LAR Depot octreotide, and Ipsen Group markets Somatuline lanreotide acetate (ITM-014...
...the market and in Novartis’ pipeline. Lutathera also targets somatostatin receptors, but unlike Sandostatin and Somatuline...
BioCentury | Sep 22, 2017
Clinical News

FDA approves Ipsen's Somatuline Depot for carcinoid syndrome

...Ipsen Group (Euronext:IPN; Pink:IPSEY) said FDA approved Somatuline Depot lanreotide acetate (ITM-014) to treat carcinoid syndrome. The extended-release...
...treat acromegaly and neuroendocrine tumors in 70 countries, and is marketed outside the U.S. as Somatuline Autogel...
...Boulogne-Billancourt, France Teijin Pharma Ltd. , Tokyo, Japan Product: Somatuline Autogel (Somatuline Depot) lanreotide acetate (ITM-014) Business: Cancer Jennie Walters ITM-014 lanreotide acetate Somatuline Autogel Somatuline Depot Ipsen...
BioCentury | Aug 16, 2017
Clinical News

Japan approves Somatuline from Ipsen and Teijin for GEP-NETs

...Ipsen Group (Euronext:IPN; Pink:IPSEY) and Teijin Pharma Ltd. (Tokyo, Japan) said Japan approved Somatuline Autogel lanreotide acetate (ITM-014...
...Somatuline Depot. Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Teijin Pharma Ltd. , Tokyo, Japan Product: Somatuline Autogel (Somatuline Depot...
...Boulogne-Billancourt, France Teijin Pharma Ltd. , Tokyo, Japan Product: Somatuline Autogel (Somatuline Depot) lanreotide acetate (ITM-014) Business: Cancer Chris Lieu ITM-014 lanreotide acetate Somatuline Autogel Somatuline Depot Ipsen...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...five products that it expected to drive growth. Two were marketed: neuroendocrine tumor product Somatuline Autogel lanreotide acetate...
...partner Inspiration Biopharmaceuticals Inc. and prostate cancer therapy tasquinimod from partner Active Biotech AB . Somatuline...
...$225.6 million) in 2010. In 2011, Ipsen set a 2020 worldwide sales goal of €500-€600. Somatuline...
BioCentury | Aug 15, 2016
Clinical News

Somatuline Depot regulatory update

...Ipsen said Teijin submitted a supplemental application in Japan for Somatuline lanreotide acetate to treat neuroendocrine tumors...
...France Teijin Pharma Ltd. , Tokyo, Japan Product: Somatuline Depot ( Somatuline Autogel - EU) lanreotide acetate ( ITM-014...
BioCentury | May 2, 2016
Analyst Picks & Changes

Analyst picks & changes

...raised his target to €63 from €50 after a survey of U.S. physicians suggests Somatuline Depot lanreotide acetate...
..."should capture a significant share" of the U.S. neuroendocrine tumor market. The company also markets Somatuline Depot...
Items per page:
1 - 10 of 79